Physician profile
Purushotham Kotha
NPI 1093730814
$1,437.40
in general payments reported to CMS, 2019-2025
20 companies · $77.21 in 2025
The $77.21 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $276 · 2021: $224 · 2022: $329 · 2023: $170 · 2024: $118 · 2025: $77.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $365.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $212.82 | 2019-2023 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $202.93 | 2019-2023 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.99 | 2020-2022 | |
| Amgen INC. | $130.19 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $93.88 | 2019-2022 | |
| Radius Health, INC. | $91.55 | 2020-2021 | |
| Ucb, INC. | $89.70 | 2023-2024 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $89.06 | 2020-2025 | Tremfya |
| Pfizer INC. | $63.49 | 2019-2023 | |
| Kiniksa Pharmaceuticals, LTD. | $52.21 | 2022-2023 | Arcalyst |
| Edwards Lifesciences Corporation | $47.49 | 2024 | Sapien 3 Ultra Resilia |
| Octapharma USA, INC. | $41.75 | 2024 | Octagam Immune Globulin (Human) |
| Astellas Pharma US INC | $34.83 | 2022 | |
| Mallinckrodt Enterprises LLC | $28.00 | 2019 | |
| Mallinckrodt Hospital Products INC. | $23.54 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $18.99 | 2022 | |
| Amarin Pharma, INC. | $17.98 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Purushotham Kotha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.